

HK CC
L (HK CC)
(OSA) (CCA) I
CCA 閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份,並直接存入中央結算及交收系統(「中央結算系統」),以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口,請使用本表格

This Application Form uses the same terms as defined in the prospectus of Shanghai Henlius Biotech, Inc. (the “**本公司**”) dated 12 September 2019 (the “**招股章程**”).

本申請表格使用上海復宏漢霖生物技術股份有限公司(「本公司」)於二零一九年九月十二日刊發的招股章程(「招股章程」)所界定的詞彙。

Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Hong Kong Offer Shares in any jurisdiction other than Hong Kong. The Hong Kong Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.

本申請表格及招股章程概不構成在香港以外司法權區要約出售或游說要約購買香港發售股份。若無根據美國證券法登記或豁免登記,香港發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. In any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction, in any manner whatsoever, copies of this Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever.

Copies of the Prospectus, all related Application Forms and the other documents specified in the “Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection – Documents Delivered to the Registrar of Companies” section in Appendix VII to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**SEHK**”), Hong Kong Securities Clearing Company Limited (“**HKCC**”), the Securities and Futures Commission of Hong Kong (the “**FC**”) and the Registrar of Companies of Hong Kong take no responsibility for the contents of these documents.

招股章程、所有相關申請表格及招股章程附錄七「送呈香港公司註冊處處長及備查文件 - 送呈公司註冊處處長文件」一節所述其他文件已遵照香港法例第32章公司(清盤及雜項條文)條例第342C條的規定,送呈香港公司註冊處處長登記。香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對此等文件的內容概不負責。



Sample Text



如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

Signed by (all) applicant(s) (all joint applicants must sign):

由(所有)申請人簽署(所有聯名申請人必須簽署):

.....

Date:

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

*(1) If you are a CCASS Investor Participant, only a Hong Kong Identity Card number (if you are an individual) or a Hong Kong Business Registration number (if you are a body corporate) will be accepted for this application, please see paragraph 2 under the section “H

--

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於

Members of the public, the Qualifying Fosun International Shareholders and the Qualifying Fosun Pharma H Shareholders who wish to obtain a copy of the printed Prospectus may obtain a copy, free of charge, upon request during normal business hours from 9:00 a.m. on Thursday, 12 September 2019 until 12:00 noon on Tuesday, 17 September 2019 at the following locations:

1. any of the following branches of the receiving banks of the Company:

Branch Name	Address
Des Voeux Road West Branch	111-119 Des Voeux Road West, Hong Kong
Chai Wan Branch	Block B, Walton Estate, 341-343 Chai Wan Road, Chai Wan, Hong Kong
Telford Plaza Branch	Shop Unit P2-P7, Telford Plaza, No.33 Wai Yip Street, Kowloon Bay, Kowloon
Olympian City Branch	Shop 133, 1/F, Olympian City 2, 18 Hoi Ting Road, Kowloon
Metro City Branch	Shop 209, Level 2, Metro City Phase 1, Tseung Kwan O, New Territories
Ma On Shan Plaza Branch	Shop 2103, Level 2, Ma On Shan Plaza, Sai Sha Road, Ma On Shan, New Territories
Head Office	45 Des Voeux Road Central
Kennedy Town Branch	28 Catchick Street
Mongkok Branch	B/F CMB Wing Lung Bank Centre, 636 Nathan Road
Tsim Sha Tsui Branch	4 Carnarvon Road
Tsuen Wan Branch	251 Sha Tsui Road

有意索取招股章程印刷本的公眾人士、合資格復星國際股東及合資格復星醫藥H股股東可於二零一九年九月十二日(星期四)上午九時正至二零一九年九月十七日(星期二)中午十二時正的正常辦公時間內，在以下地點免費索取：

1. 本公司收款銀行的下列任何分行：

中國銀行(香港)有限公司

總區	分行名稱	地址
香港島	德輔道西分行	香港德輔道西111-119號
	柴灣分行	香港柴灣道341-343號宏德居B座
九龍	德福廣場分行	九龍灣偉業街33號德福廣場P2-P7號舖
	奧海城分行	九龍海庭道18號奧海城二期一樓133號
新界	新都城分行	新界將軍澳新都城一期二樓209號
	馬鞍山廣場分行	新界馬鞍山西沙路馬鞍山廣場L2層2103號

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於

2. any of the following offices of the below Joint Global Coordinators:

29th Floor, One International Finance Centre
1 Harbour View Street
Central
Hong Kong

Level 55 Cheung Kong Center
2 Queen's Road Central
Central
Hong Kong

26th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong

52/F, Two International Finance Centre
8 Finance Street
Central
Hong Kong

45/F, Champion Tower
3 Garden Road
Central
Hong Kong

Suite 2101-2105 21/F Champion Tower
3 Garden Road
Central
Hong Kong

3. the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

During normal business hours from 9:00 a.m. on Thursday, 12 September 2019 until 12:00 noon on Tuesday, 17 September 2019, at least three copies of the printed Prospectus will be available for inspection at every location where the HIFE and ELL Application Forms are distributed as set out in the section headed "How to Apply for Hong Kong Offer Shares and Reserved Shares" in the Prospectus. You should read the Prospectus prior to submitting this Application Form.

During normal business hours from 9:00 a.m. on Thursday, 12 September 2019 until 12:00 noon on Tuesday, 17 September 2019, at least three copies of the printed Prospectus will be available for inspection at every location where the HIFE and ELL Application Forms are distributed as set out in the section headed "How to Apply for Hong Kong Offer Shares and Reserved Shares" in the Prospectus. You should read the Prospectus prior to submitting this Application Form.

2. 以下聯席全球協調人的下列任何辦事處：

中國國際金融香港證券有限公司
香港
中環
港景街1號
國際金融中心一期29樓

香港
中環
皇后大道中2號
長江集團中心55樓

中銀國際亞洲有限公司
香港
中環
花園道1號
中銀大廈26樓

香港
中環
金融街8號
國際金融中心二期52樓

招銀國際融資有限公司
香港
中環
花園道3號
冠君大廈45樓

復星恆利證券有限公司
香港
中環
花園道3號
冠君大廈21樓2101-2105室

3. 香港結算存管處服務櫃檯，地址為香港中環康樂廣場8號交易廣場一座及二座一樓。

可索取招股章程印刷本的地址詳情將於派發白色及黃色申請表格的各個地點以顯眼方式展示。

於二零一九年九月十二日(星期四)上午九時正至二零一九年九月十七日(星期二)中午十二時正的正常辦公時間內，在派發白色及黃色申請表格的各個地點(載於招股章程「如何申請香港發售股份及預留股份」)，均有至少三份招股章程印刷本可供查閱。閣下提交本申表格前須閱讀招股章程。

Sample 樣版

This page is intentionally left blank
此乃白頁 特意留空

4. Tear off the Application Form, fold it once and lodge your completed Application Form (with cheque or banker's cashier order attached) to one of the collection boxes at any of the following branches of Bank of China (Hong Kong) Limited and CMB Wing Lung Bank Limited:

<p>Bank of China (Hong Kong) Limited</p> <p>Des Voeux Road West Branch</p> <p>Chai Wan Branch</p> <p>Telford Plaza Branch</p> <p>Olympian City Branch</p>	<p>Des Voeux Road West Branch</p> <p>Chai Wan Branch</p> <p>Telford Plaza Branch</p> <p>Olympian City Branch</p>	<p>111-119 Des Voeux Road West, Hong Kong</p> <p>Block B, Walton Estate, 341-343 Chai Wan Road, Chai Wan, Hong Kong</p> <p>Shop Unit P2-P7, Telford Plaza, No.33 Wai Yip Street, Kowloon Bay, Kowloon</p> <p>Shop 133, 1/1(tB9)1(Y)1(1(n)JEMCEMF(1(n)In City B</p>
--	--	---

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

申請手續

1. 使用下表計算閣下應付的款項。閣下申請認購的股數須至少為100股香港發售股份，並為下表所列的其中一個數目，否則恕不受理。

可供申請認購的香港發售股份數目及應繳款項							
申請認購的 香港發售 股份數目	申請時 應繳款項 (港元)	申請認購的 香港發售 股份數目	申請時 應繳款項 (港元)	申請認購的 香港發售 股份數目	申請時 應繳款項 (港元)	申請認購的 香港發售 股份數目	申請時 應繳款項 (港元)
100	5,838.25	3,500	204,338.58	70,000	4,086,771.54	2,000,000	116,764,901.20
200	11,676.49	4,000	233,529.80	80,000	4,670,596.05	2,500,000	145,956,126.50
300	17,514.74	4,500	262,721.03	90,000	5,254,420.55	3,000,000	175,147,351.80
400	23,352.98	5,000	291,912.25	100,000	5,838,245.06	3,234,800 ⁽¹⁾	188,855,551.20
500	29,191.23	6,000	350,294.70	200,000	11,676,490.12		
600	35,029.47	7,000	408,677.15	300,000	17,514,735.18		
700	40,867.71	8,000	467,059.60	400,000	23,352,980.24		
800	46,705.96	9,000	525,442.06	500,000	29,191,225.30		
900	52,544.20	10,000	583,824.51	600,000	35,029,470.36		
1,000	58,382.45	20,000	1,167,649.01	700,000	40,867,715.42		
1,500	87,573.68	30,000	1,751,473.52	800,000	46,705,960.48		
2,000	116,764.90	40,000	2,335,298.02	900,000	52,544,205.54		
2,500	145,956.13	50,000	2,919,122.53	1,000,000	58,382,450.60		
3,000	175,147.35	60,000	3,502,947.04	1,500,000	87,573,675.90		

⁽¹⁾ 閣下可申請認購的香港發售股份最高數目。

2. 閣下作為申請人，必須按照下列指示以英文正楷填妥表格，並於申請表格次頁簽署，只接納親筆簽名(不得以個人印章代替)。

如閣下透過中央結算系統投資者戶口持有人以外的指定中央結算系統參與者提出申請：該指定中央結算系統參與者必須於表格蓋上公司印鑑(附有公司名稱)，並在適當方格內填寫參與者編號。

如閣下以個人中央結算系統投資者戶口持有人名義提出申請：表格須載有閣下的姓名和香港身份證號碼。

須在適當方格內填寫閣下的參與者編號。

如閣下以聯名個人中央結算系統投資者戶口持有人名義提出申請：表格須載有所有聯名投資者戶口持有人的姓名和香港身份證號碼；須在適當方格內填寫閣下的參與者編號。

如閣下以公司中央結算系統投資者戶口持有人名義提出申請：

表格須載有閣下的公司名稱和香港商業登記號碼；

須在適當方格內填寫閣下的參與者編號並蓋上公司印鑑(附有公司名稱)。

中央結算系統參與者的資料(包括參與者編號及或顯示公司名稱之公司印鑑)或其他類似事項如有不確或遺漏，均可能導致申請無效。

3. 閣下須將支票或銀行本票釘於表格上。每份香港發售股份申請須附一張獨立開出支票或一張獨立開出銀行本票。支票或銀行本票必須符合以下所有規定，否則有關的認購申請不獲接納：

支票必須：	銀行本票必須：
為港元； 不得為期票； 註明抬頭人為「中國銀行(香港)代理人有限公司 - 復宏漢霖生物技術公開發售」； 劃線註明「只准入抬頭人賬戶」；	須由香港持牌銀行開出，並由有關銀行授權的人士在銀行本票背面簽署核證閣下姓名名稱。銀行本票所示姓名名稱須與閣下姓名名稱相同。如屬聯名申請，銀行本票背面所示姓名名稱必須與排名首位申請人的姓名名稱相同。
從閣下在香港的港元銀行賬戶中開出；及 顯示閣下的賬戶名稱，而該賬戶名稱必須已預印在支票上，或由有關銀行授權的人士在支票背書。賬戶名稱必須與閣下姓名名稱相同。如屬聯名申請，賬戶名稱必須與排名首位申請人的姓名名稱相同。	

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

4. 請撕下申請表格，對摺一次，然後將填妥的申請表格(連同支票或銀行本票)投入下列中國銀行(香港)有限公司及招商永隆銀行有限公司的任何一家分行特設的收集箱：

中國銀行(香港)有限公司

地區	分行名稱	地址
香港島	德輔道西分行	香港德輔道西 111-119 號
	柴灣分行	香港柴灣道 341-343 號宏德居 B 座
九龍	德福廣場分行	九龍灣偉業街 33 號德福廣場 P2-P7 號舖
	奧海城分行	九龍海庭道 18 號奧海城二期一樓 133 號
新界	新都城分行	新界將軍澳新都城一期二樓 209 號
	馬鞍山廣場分行	新界馬鞍山西沙路馬鞍山廣場 L2 層 2103 號

招商永隆銀行有限公司

地區	分行名稱	地址
香港島	總行	德輔道中 45 號
	堅尼地城分行	吉席街 28 號
九龍	旺角分行	彌敦道 636 號招商永隆銀行中心地庫
	尖沙咀分行	加拿分道 4 號
新界	荃灣分行	沙咀道 251 號

5. 閣下可於下列時間遞交申請表格：

二零一九年九月十二日(星期四) - 上午九時正至下午五時正
二零一九年九月十三日(星期五) - 上午九時正至下午五時正
二零一九年九月十六日(星期一) - 上午九時正至下午五時正
二零一九年九月十七日(星期二) - 上午九時正至中午十二時正

6. 截止遞交申請的時間為二零一九年九月十七日(星期二)中午十二時正。本公司將於當日上午十一時四十五分至中午十二時正期間登記認購申請，唯一會影響此時間的變化因素為當日的天氣情況(詳見招股章程「如何申請香港發售股份及預留股份」一節「D. 惡劣天氣對開始及截止辦理申請登記的影響」)。

香港發售股份申請將會自二零一九年九月十二日(星期四)起直至二零一九年九月十七日(星期二)止。申請款項(包括經紀佣金、證監會交易徵費及聯交所交易費)將由收款銀行於截止辦理申請登記後代表本公司持有，且退款金額(如有)將於二零一九年九月二十四日(星期二)或之前不計利息退還予申請人。投資者務請注意，預期H股將於二零一九年九月二十五日(星期三)於聯交所開始買賣。



Henlius

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

重要提示

A.

1. You and any person(s) for whose benefit you are applying must be 18 years of age or older and must have a Hong Kong address.
2. If you are a firm, the application must be in the individual members' names.
3. The number of joint applicants may not exceed 4.
4. If you are a body corporate, the application must be signed by a duly authorised officer, who must state his representative capacity, and stamped with your corporation's chop.
5. You must be outside the United States, not be a United States Person (within the meaning of Regulation S) or a person described in paragraph (h)(3) of Rule 902 of Regulation S and not be a legal or natural person of the PRC (except qualified domestic institutional investors).
6. Unless permitted by the Listing Rules and guidance letters issued by the Stock Exchange, or any relevant waivers that have been granted by the Stock Exchange, you cannot apply for any Hong Kong Offer Shares if you are:
 - an existing beneficial owner of shares in the Company and/or any of its subsidiaries;
 - a director or chief executive officer of the Company and/or any of its subsidiaries;
 - an associate of any of the above;
 - a connected person of the Company or will become a connected person of the Company immediately upon completion of the Global Offering; or
 - have been allocated or have applied for or indicated an interest in any Offer Shares under the International Offering (except in respect of Reserved Shares applied for pursuant to the Preferential Offering).

B. 重要提示

You, as a nominee, may make more than one application for the Hong Kong Offer Shares by: (i) giving electronic instructions to HKSCC via Central Clearing and Settlement System ("CCASS") (if you are a CCASS Participant); or (ii) using a HFE or ELL Application Form, and lodge more than one application in your own name on behalf of different beneficial owners.

C. 重要提示

By completing and submitting this Application Form, you (and if you are joint applicants, each of you jointly and severally) for yourself or as an agent or a nominee on behalf of each person for whom you act:

to execute all relevant documents and instruct and authorise the Company and/or the Joint Representatives (or their agents or nominees), as agents of the Company, to execute any documents for you and to do on your behalf all things necessary to register any Hong Kong Offer Shares allocated to you in the name of HKSCC Nominees as required by the Articles of Association;

to comply with the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) and the Articles of Association;

that you have read the terms and conditions and application procedures set out in the Prospectus and in this Application Form and agree to be bound by them;

that you have received and read the Prospectus and have only relied on the information and representations contained in the Prospectus in making your application and will not rely on any other information or representations except those in any supplement to the Prospectus* (h)1 (;50u;.50u0JEM50u0

that each of HKSCC and HKSCC Nominees reserves the right (1) not to accept any or part of such allotted shares issued in the name of HKSCC Nominees or not to accept such allotted shares for deposit into CCASS; (2) to cause such allotted shares to be withdrawn from CCASS and issued in your name at your own risk and costs; and (3) to cause such allotted shares to be issued in your name (or, if you are a joint applicant, to the first-named applicant) and in such a case, to post the certificates for such allotted shares at your own risk to the address on your application form by ordinary post or to make available the same for your collection;

that each of HKSCC and HKSCC Nominees may adjust the number of allotted shares issued in the name of HKSCC Nominees;

that neither HKSCC nor HKSCC Nominees shall have any liability for the information and representations not so contained in the Prospectus and this application form;

that neither HKSCC nor HKSCC Nominees shall be liable to you in any way;

and that except for an application made in the capacity as a Qualifying Fosun International Shareholder or a Qualifying Fosun Pharma H Shareholders under the Preferential Offering, this is the only application made and the only application intended by you to be made to benefit you or the person for whose benefit you are applying;

understand that the Company and the Joint Representatives will rely on your declarations and representations in deciding whether or not to make any allotment of any of the Hong Kong Offer Shares to you and that you may be prosecuted for making a false declaration;

(if the application is made for your own benefit) that no other application has been or will be made for your benefit on a HIF E or ELL Application Form or by giving electronic application instructions to HKSCC or to the F.I. Service Provider by you or by any one as your agent or by any other person; and

(if you are making the application as an agent for the benefit of another person) that (i) no other application has been or will be made by you as agent for or for the benefit of that person or by that person or by any other person as agent for that person on a HIF E or ELL Application Form or by giving electronic application instructions to HKSCC; and (ii) you have due authority to sign the Application Form or give electronic application instructions on behalf of that other person as its agent.

D. If your application is made through an authorised attorney, the Company and the Joint Representatives may accept or reject your application at their discretion, and on any conditions they think fit, including evidence of the attorney's authority.

D. The Offer Price is expected to be fixed on or around Tuesday, 17 September 2019. Applicants are required to pay the maximum Offer Price of HK\$57.80 for each Hong Kong Offer Share together with 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee. If the Offer Price is not agreed among the Company and the Joint Representatives (for themselves and on behalf of the Underwriters) on or before Tuesday, 24 September 2019, the Global Offering will not proceed.

Applications for Hong Kong Offer Shares will not be processed and no allotment of any Hong Kong Offer Shares will be made until the application lists close.

The Company expects to announce the final Offer Price, the indication of the level of interest in the International Offering, the level of applications under the Hong Kong Public Offering and the Preferential Offering and the basis of allocation of the Hong Kong Offer Shares and the Reserved Shares on Tuesday, 24 September 2019 in South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese) and on the website of the Stock Exchange at www.hkex.com.hk and the Company's website at www.fosun.com.hk. Results of allocations and the Hong Kong Identity Card/passport

Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering and the Preferential Offering (where applicable) will be available on the above websites.

If your application is wholly or partially successful, your Share certificate(s) (subject to their becoming valid certificates of title provided that the Hong Kong Public Offering has become unconditional and not having been terminated at 8:00 a.m. on Wednesday, 25 September 2019) will be issued in the name of HKSCC Nominees and deposited directly into CCASS for credit to your CCASS Investor Participant stock account or the stock account of your designated CCASS Participant as instructed by you in your Application Form on Tuesday, 24 September 2019 or, in the event of a contingency, on any other date as shall be determined by HKSCC or HKSCC Nominees.

If you are applying through a designated CCASS Participant (other than a CCASS Investor Participant): For Hong Kong Offer Shares credited to the stock account of your designated CCASS Participant (other than a CCASS Investor Participant), you can check the number of Hong Kong Offer Shares allotted to you with that CCASS Participant.

If you are applying as a CCASS Investor Participant: The Company expects to publish the results of CCASS Investor Participants' applications together with the results of the Hong Kong Public Offering in South China Morning Post (in English) and Hong Kong Economic Times (in Chinese) on Tuesday, 24 September 2019. You should check the announcement published by the Company and report any discrepancies to HKSCC before 5:00 p.m. on Tuesday, 24 September 2019 or such other date as shall be determined by HKSCC or HKSCC Nominees. Immediately after the credit of the Hong Kong Offer Shares to your stock account you can check your new account balance via the CCASS Phone System and CCASS Internet System (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time). HKSCC will also make available to you an activity statement showing the number of Hong Kong Offer Shares credited to your stock account.

No receipt will be issued for application money paid. The Company will not issue temporary documents of title.

If you do not receive any Hong Kong Offer Shares or if your application is accepted only in part, the Company will refund to you your application monies (including the related 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee) without interest. If the Offer Price is less than the maximum Offer Price, the Company will refund to you the surplus application monies (including the related 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee) without interest.

The refund procedures are stated in the "H. Despatch/Collection of Share Certificates/e-Refund Payment Institutions/Refund Cheque" in the "How to Apply for Hong Kong Offer Shares and Reserved Shares" section of the Prospectus.

Computershare Hong Kong Investor Services Limited and its related bodies' corporate, directors, officers, employees and agents (collectively "Computershare") expressly disclaim and exclude to the maximum extent permitted by law any liability for any loss or damage suffered or incurred by the applicant or any other person or entity however caused relating in any way to, or connected with, any information provided by or on behalf of the applicant on or in connection with this document or any services provided hereunder, or any other written or oral communication provided by or on behalf of the applicant in connection with this document or any services provided hereunder. This includes, without limitation, any errors or omissions in such information however caused, or the Representatives or any other person or entity placing any reliance on such information or any documentation, image, recording or reproduction of such information, or its accuracy, completeness, currency or reliability.

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

申請條件

甲、可提出申請的人士

1. 閣下及閣下為其利益提出申請的人士必須年滿18歲並有香港地址。
2. 如閣下為商號，申請須以個別成員名義提出。
3. 聯名申請人不得超過四名。
4. 如閣下為法人團體，申請須經獲正式授權人員簽署，並註明其所屬代表身份及蓋上公司印鑑。
5. 閣下必須身處美國境外，並非美籍人士(定義見S規例)或屬S規例第902條第(h)(3)段所述的人士，亦非中國法人或自然人(惟合資格境內機構投資者除外)。
6. 除上市規則及聯交所發出的指引信或聯交所已授予的任何相關豁免批准外，下列人士概不得申請認購任何香港發售股份：
 - 本公司及或其任何子公司股份的現有實益擁有人；
 - 本公司及或其任何子公司的董事或行政總裁；
 - 上述任何人士的聯繫人；
 - 本公司關連人士或緊隨全球發售完成後成為本公司關連人士的人士；或
 - 已獲分配或已申請或表示有意申請國際發售的任何發售股份(根據優先發售申請預留股份除外)。

乙、如閣下為代名人

閣下作為代名人可提交超過一份香港發售股份申請，方法是：(i)透過中央結算及交收系統(「中央結算系統」)向香港結算發出電子認購指示(如閣下為中央結算系統參與者)；或(ii)使用白色或黃色申請表格以自身名義代表不同的實益擁有人提交超過一份申請。

丙、填交本申請表格的效用

閣下填妥並遞交本申請表格，即表示閣下(如屬聯名申請人，即各人共同及個別)代表閣下本身，或作為閣下代其行事的每位人士的代理或代名人：

承諾簽立所有相關文件，並指示及授權本公司及或聯席代表(或彼等的代理或代名人)作為本公司代理，為按照章程細則的規定將閣下獲分配的任何香港發售股份以香港結算代理人的名義登記而代表閣下簽立任何文件；

同意遵守香港法例第622章公司條例、香港法例第32章公司(清盤及雜項條文)條例及章程細則；

確認

及條件以及申請程序，並同意受其約束；

確認閣下已接獲及細閱招股章程，提出申請時也僅依據招股章程(不計其間)為準，而除招股章程任何補充文件外，不會依賴任何其他資料或陳述；顯切補充文件外，不會依賴任何其他資料或陳述；

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

名義發行(或如屬聯名申請人，則以排名首位申請人的名義發行)，而在此情況下，會以普通郵遞方式將該等獲配發股份的股票寄往閣下在申請表格上所示地址(郵誤風險概由閣下自行承擔)或提供該等股票予閣下領取；

同意香港結算及香港結算代理人均可調整獲配發以香港結算代理人名義發行的股份數目；

同意香港結算及香港結算代理人對招股章程及本申請表格未有載列的資料及陳述概不負責；

同意香港結算及香港結算代理人概不以任何方式對閣下負責；

聲明及表示除以合資格復星國際股東或合資格復星醫藥H股股東身份根據優先發售所提交的申請外，此乃閣下為本身或閣下為其利益提出申請的人士提出及擬提出的唯一申請；

明白本公司及聯席代表將依據閣下的聲明及陳述而決定是否向閣下分配任何香港發售股份，閣下如作出虛假聲明，可能會被檢控；

(如本申請是為閣下本身利益提出)保證閣下或作為閣下代理的任何人士或任何其他人士不曾亦不會為閣下利益而以白色或黃色申請表格或向香港結算或向白表 I 服務供應商發出電子認購指示而提出其他申請；及

(如閣下作為代理為另一人士的利益提出申請)保證(i) 閣下(作為代理或為該人士利益)或該人士或任何其他作為該人士代理的人士不曾亦不會以白色或黃色申請表格或向香港結算發出電子認購指示而提出其他申請；及(ii) 閣下獲正式授權作為該人士的代理代為簽署本申請表格或發出電子認購指示。

丁、授權書

如閣下透過授權人士提出申請，本公司及聯席代表可按其認為合適的條件(包括出示獲授權證明)酌情接納或拒絕閣下的申請。

釐定發售價及香港發售股份的分配

D

I

This Personal Information Collection Statement informs the applicant for, and holder of, Hong Kong Offer Shares, of the policies and practices of the Company and its H Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the "Ordinance").

1. It is necessary for applicants and registered holders of securities to supply correct personal data to the Company or its agents and the H Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the H Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected, or in delay or the inability of the Company or its H Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of Share certificate(s) and/or refund cheque(s) to which you are entitled.

It is important that securities holders inform the Company and the H Share Registrar immediately of any inaccuracies in the personal data supplied.

2. The personal data of the securities holders may be used, held, processed, and/or stored (by whatever means) for the following purposes:

- processing your application and refund cheque, where applicable, verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of securities' holders including, where applicable, HKSCC Nominees;
- maintaining or updating the register of securities' holders of the Company;
- verifying securities holders' identities;
- establishing benefit entitlements of securities' holders of the Company, such as dividends, rights issues, bonus issues, etc.;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and securities' holders profiles;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the

H Share Registrar to discharge their obligations to securities' holders and/or regulators and/or any other purposes to which the securities' holders may from time to time agree.

3. Personal data held by the Company and its H Share Registrar relating to the securities holders will be kept confidential but the Company and its H Share Registrar may, to the extent necessary for achieving any of the above purposes, disclose, obtain or transfer (whether within or outside Hong Kong) the personal data to, from or with any of the following:

- the Company's appointed agents such as financial advisers, receiving bankers and overseas principal share registrar; where applicants for securities request a deposit into CCASS, HKSCC or HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company H Share Registrar in connection with their respective business operation;
- the Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any persons or institutions with which the securities' holders have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers etc.

4. The Company and its H Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. A Securities holders have the right to ascertain whether the Company or the H Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the H Share Registrar have the right to charge a reasonable fee for the processing of such requests.

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the "Corporate Information" section of the Prospectus or as notified from time to time, for the attention of the company secretary, or our H Share Registrar for the attention of the privacy compliance officer.

B App F HK CC

如閣下欲以香港中央結算(代理人)有限公司(「香港結算代理人」)的名義登記將獲發行的香港發售股份，並直接存入中央結算及交收系統(「中央結算系統」)，以記存於閣下的中央結算系統投資者戶口持有人股份戶口或閣下指定的中央結算系統參與者股份戶口，請使用本表格

個人資料

個人資料收集聲明

此項個人資料收集聲明是向香港發售股份的申請人和持有人說明有關本公司及其H股證券登記處有關個人資料和香港法例第486章《個人資料(私隱)條例》(「條例」)方面的政策和慣例。

1. 收集閣下個人資料的原因

證券申請人及登記持有人以本身名義申請證券或轉讓或受讓證券時或尋求H股證券登記處的服務時，必須向本公司或其代理人及H股證券登記處提供準確個人資料。

未能提供所要求的資料可能導致閣下申請證券被拒或延遲，或本公司或其H股證券登記處無法落實轉讓或提供服務。此舉也可能妨礙或延遲登記或轉讓閣下成功申請的香港發售股份及或寄發閣下應得的股票及或退款支票。

證券持有人所提供的個人資料如有任何錯誤，須立即通知本公司及H股證券登記處。

2. 目的

證券持有人的個人資料可被採用及以任何方式持有、處理及或保存，以作下列用途：

處理閣下的申請及退款支票(如適用)、核實是否符合本申請表格及招股章程載列的條款和申請程序以及公佈香港發售股份的分配結果；

遵守香港及其他地區的適用法律及法規；

以證券持有人(包括香港結算代理人(如適用))的名義登記新發行證券或轉讓或受讓證券；

存置或更新本公司證券持有人的名冊；

核實證券持有人的身份；

確定本公司證券持有人的受益權利，例如股息、供股和紅股等；

分發本公司及其附屬公司的通訊；

編製統計數據和證券持有人資料；

披露有關資料以便就權益索償；及

與上述有關的任何其他附帶或相關目的及

或使本公司及H股證券登記處能履行對證券

持有人及或監管機構承擔的責任及或證券持有人不時同意的任何其他目的。

3. 轉交個人資料

本公司及其H股證券登記處所持有關證券持有人的個人資料將會保密，但本公司及其H股證券登記處可以在為達到上述任何目的之必要情況下，向下列任何人士披露，獲取或轉交(無論在香港境內或境外)有關個人資料：

本公司委任的代理人，例如財務顧問、收款銀行和主要海外股份過戶登記分處；

(如證券申請人要求將證券存於中央結算系統)香港結算或香港結算代理人；彼等將會就中央結算系統的運作使用有關個人資料；向本公司或H股證券登記處提供與其各自業務營運有關的行政、電訊、電腦、付款或其他服務的任何代理人、承包商或第三方服務供應商；

聯交所、證監會及任何其他法定監管機關或政府部門或遵照其他法例、規則或法規；及證券持有人與其進行或擬進行交易的任何人士或機構，例如彼等的銀行、律師、會計師或股票經紀等。

4. 個人資料的保留

本公司及其H股證券登記處將按收集個人資料所需的用途保留證券申請人及持有人的個人資料。無需保留的個人資料將會根據條例銷毀或處理。

5. 查閱和更正個人資料

證券持有人有權確定本公司或H股證券登記處是否持有其個人資料，並有權索取有關該資料的副本並更正任何不準確資料。本公司和H股證券登記處有權就處理任何查閱資料的要求收取合理費用。

所有查閱資料或更正資料的要求應按招股章程「公司資料」一節所披露或不時通知的本公司註冊地址送交公司秘書，或向本公司的H股證券登記處的個人資料私隱事務主任提出。

閣下簽署申請表格或向香港結算發出電子認購指示，即表示同意上述各項。